Bio-Rad Laboratories (NYSE:BIO.B) Share Price Crosses Above Fifty Day Moving Average - Here's Why

Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $301.26 and traded as high as $310.70. Bio-Rad Laboratories shares last traded at $310.70, with a volume of 82 shares.Get Bio-Rad Laboratories alerts:Bio-Rad Laboratories Price PerformanceThe company has a debt-to-equity ratio of 0.18, a quick ratio of 3.94 and a current ratio of 5.44. The stock's 50-day moving average is $301.26 and its two-hundred day moving average is $268.94. The stock has a market cap of $8.38 billion, a PE ratio of -12.78 and a beta of 1.02. Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last released its quarterly earnings results on Wednesday, October 29th. The company reported $2.26 EPS for the quarter. Bio-Rad Laboratories had a positive return on equity of 4.19% and a negative net margin of 26.43%.The company had revenue of $653.00 million for the quarter. About Bio-Rad Laboratories (Get Free Report)Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.Featured ArticlesFive stocks we like better than Bio-Rad LaboratoriesHow to buy stock: A step-by-step guide for beginners Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?What is the Hang Seng index? Checkmate in the Cloud: ServiceNow's Shopping SpreeThe Significance of a Trillion-Dollar Market Cap Goes Beyond a NumberThe Contrarian Case for MSTR Amid MSCI Delisting DebacleThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Bio-Rad Laboratories Right Now?Before you consider Bio-Rad Laboratories, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.While Bio-Rad Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here